Ad Cure Roadmap — Integrated Timeline is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
A comprehensive roadmap for Alzheimer's disease therapeutic development, synthesized from evidence-based scoring of approaches and systematic analysis of past failures.
¶ AD Cure Roadmap — Integrated Timeline > A comprehensive roadmap for Alzheimer's disease therapeutic development, synthesized from evidence-based scoring of approaches and systematic analysis of past failures.
This page synthesizes the evidence from rs001-rs007 into a concrete, actionable roadmap. The analysis reveals that:
- Lifestyle interventions score highest (60/70) but only prevent — not treat — established disease
- Anti-amyloid antibodies lead pharmacotherapy (55/70) with 27-35% cognitive slowing
- Combination therapy is essential to break through the single-target ceiling (~27%)
- GLP-1 agonists are the strongest near-term repurposing candidate (54/70)
gantt
title AD Cure Roadmap — Parallel Development Tracks
dateFormat YYYY
axisFormat %Y
section Immediate (2024-2026)
Approved anti-amyloid optimization :active, imm1, 2024, 2y
Lifestyle intervention rollout :active, imm2, 2024, 2y
GLP-1 repurposing (EVOKE trials) :active, imm3, 2024, 2y
section Near-Term (2026-2030)
Anti-amyloid + anti-tau combo :crit, near1, 2026, 3y
Anti-amyloid + GLP-1 combo :near2, 2026, 3y
Focused ultrasound enhancement :near3, 2026, 2y
Prevention trials (DIAN-TU, A4) :near4, 2026, 4y
TREM2 agonists (AL002) :near5, 2027, 3y
section Medium-Term (2030-2035)
Gene therapy (AAV-BDNF/NGF) :med1, 2030, 5y
Microglial reprogramming :med2, 2031, 4y
Precision medicine (APOE-stratified) :med3, 2030, 5y
Anti-tau ASOs (BIIB080) :med4, 2030, 5y
section Long-Term (2035-2045)
True disease modification :long1, 2035, 10y
Regenerative therapies :long2, 2035, 10y
Multi-target combination cocktails :crit, long3, 2035, 10y
Top Approaches from rs001:
| Rank |
Approach |
Score |
Key Action |
| 1 |
Anti-amyloid antibodies (Lecanemab, Donanemab) |
55 |
Expand access, optimize dosing |
| 10 |
Lifestyle interventions (exercise, diet, sleep) |
60 |
Implement Lancet Commission recommendations |
| 2 |
GLP-1 agonists (Semaglutide) |
54 |
Await EVOKE/EVOKE-Spark results |
Key Gaps from rs002:
- Why does amyloid removal only slow decline 27%? (Impact: 10, Tractability: 6)
- What triggers the switch from normal aging to AD? (Impact: 9, Tractability: 5)
- Resilience factors in amyloid-positive non-demented (Impact: 9, Tractability: 7)
Patient Action TODAY:
- If diagnosed early (MCI or early AD): Request anti-amyloid antibody treatment
- Implement lifestyle modifications immediately
- Consider GLP-1 if available off-label for metabolic health
Top Approaches from rs001:
| Rank |
Approach |
Score |
Key Action |
| 4 |
Combination therapy (anti-amyloid + anti-tau) |
51 |
Initiate Phase 3 combo trials |
| 5 |
Focused ultrasound + drug delivery |
50 |
Test with anti-amyloid antibodies |
| 3 |
Anti-tau antibodies (E2814, Bepranemab) |
52 |
Continue Phase 2/3 |
Key Gaps from rs002:
- Does tau spread cause neurodegeneration or is it a bystander? (Impact: 9, Tractability: 7)
- What is the role of the immune system in early vs late AD? (Impact: 9, Tractability: 6)
- What causes selective vulnerability of specific brain regions? (Impact: 8, Tractability: 5)
Researcher Focus:
- Design adaptive combination trials with biomarker stratification
- Develop tau PET endpoints for combination studies
- Explore FUS-enhanced antibody delivery
Top Approaches from rs001:
| Rank |
Approach |
Score |
Key Action |
| 8 |
Gene therapy (AAV-BDNF, AAV-NGF) |
46 |
Advance to Phase 2 |
| 9 |
Microglial reprogramming |
46 |
Target DAM pathway |
| 12 |
TREM2 agonists (AL002) |
47 |
Complete Phase 2/3 |
Key Gaps from rs002:
- Is AD one disease or several with shared symptoms? (Impact: 10, Tractability: 4)
- What role do viral infections (HSV-1, HHV-6) play? (Impact: 7, Tractability: 6)
- Why do women get AD 2x more than men? (Impact: 8, Tractability: 5)
Funder Priority:
- Support gene therapy vector development for brain delivery
- Fund microglial biology research (understudied)
- Require sex-stratified analysis in all trials
Approaches to Develop:
- Regenerative therapies (stem cells, neurotrophic factors)
- Multi-target "cocktail" approaches
- Personalized prevention based on genetic risk
Key Gaps from rs002:
- Can we regenerate lost neurons? (Impact: 10, Tractability: 2)
- What is the role of the microbiome-gut-brain axis? (Impact: 8, Tractability: 6)
- Can we prevent AD before any symptoms? (Impact: 10, Tractability: 5)
flowchart TD
A[New AD Diagnosis] --> B{Stage?}
B -->|Preclinical| C[Enroll in prevention trial] -->
B -->|MCI/ Early AD| D[Request Lecanemab/Donanemab] -->
B -->|Moderate| E[Consider GLP-1 trials] -->
D --> F[Implement lifestyle changes] -->
E --> F
C --> F
F --> G[Monitor with amyloid PET, tau PET] -->
G --> H{Progresses?}
H -->|Yes| I[Consider combo trials] -->
H -->|No| J[Continue maintenance]
Patient Checklist:
- Get biomarker confirmation (amyloid PET or CSF)
- If early stage: Request anti-amyloid antibody
- Start lifestyle interventions (exercise, MIND diet, sleep)
- Consider GLP-1 if available
- Join clinical trial registry (ClinicalTrials.gov)
- Monitor with annual cognitive assessments
flowchart TD
A[Researcher: Choose Focus] --> B{Question Type?}
B -->|Mechanism| C[Target: Microglial biology] -->
B -->|Therapeutic| D[Approach: Combination therapy] -->
B -->|Prevention| E[Trial Design: Biomarker-defined] -->
C --> F[Read: rs002 gaps on immunity] -->
D --> G[Read: rs003 combo matrix] -->
E --> H[Read: rs006 prevention scorecard] -->
F --> I[Publish: 3-year plan] -->
G --> I
H --> I
Researcher Priorities:
- Immediate: Design combination trials (anti-amyloid + anti-tau)
- Near-term: Develop better tau PET ligands
- Medium-term: Investigate microglial pathways
- Long-term: Explore regenerative approaches
flowchart TD
A[Funder: Allocate Resources] --> B{Risk Tolerance?}
B -->|Conservative| C[Fund: Repurposing (GLP-1)] -->
B -->|Moderate| D[Fund: Combination trials] -->
B -->|Aggressive| E[Fund: Novel mechanisms] -->
C --> F[Priority: Phase 3 trials] -->
D --> G[Priority: Adaptive combo designs] -->
E --> H[Priority: Gene therapy, regeneration] -->
F --> I[Expected ROI: 3-5 years] -->
G --> J[Expected ROI: 5-7 years] -->
H --> K[Expected ROI: 10+ years]
Funder Priority Matrix:
| Approach |
Risk |
Potential Impact |
Recommendation |
| GLP-1 repurposing |
Low |
Medium |
Fund Phase 3 |
| Anti-amyloid + anti-tau |
Medium |
High |
Fund combo trials |
| Gene therapy |
High |
Very High |
Seed investment |
| Multi-target cocktails |
Medium |
Very High |
Coordinate initiative |
Based on rs002 gap analysis and rs005 failure patterns:
#1 Priority: Understanding Why Amyloid Removal Only Slows Decline 27%
Why this matters:
- Current approved therapies hit the "amyloid target" but don't stop neurodegeneration
- Solving this reveals the missing mechanism
- Would transform all other approaches
Research pathway:
- Test: Does tau removal enhance anti-amyloid benefit?
- Hypothesis: Amyloid removal needs complementary neuroprotection
- Experiment: Biomarker stratification in combo trials
- Outcome: True disease modification
If solved, this accelerates:
- Immediate: Better anti-amyloid optimization
- Near-term: Effective combinations
- Medium-term: Precision medicine targets
- Long-term: Regenerative combination cocktails
The study of Ad Cure Roadmap — Integrated Timeline has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
-
van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.
-
Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease. JAMA. 2023;330(6):512-527.
-
Livingston G, et al. Dementia prevention, intervention, and care: 2024 report. Lancet. 2024;404(10456):572-628.
-
Huang LK, et al. Combination therapy for Alzheimer's disease: opportunities and challenges. Trends Pharmac Sci. 2024;45(3):212-227.
-
Hölscher C. GLP-1 analogues as neuroprotective agents in Alzheimer's disease. Nat Rev Neurosci. 2024;25(8):527-542.
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
5 references |
| Replication |
100% |
| Effect Sizes |
50% |
| Contradicting Evidence |
100% |
| Mechanistic Completeness |
50% |
Overall Confidence: 59%